Wednesday, November 11, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· June 12, 2026

The AI bubble looks fit to burst, Bank of America director says. Here’s your road map for riding out a crash

View original at finance.yahoo.com
The AI bubble looks fit to burst, Bank of America director says. Here’s your road map for riding out a crash Moneywise and Yahoo Finance LLC may earn commission or revenue through links in the content below…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The AI bubble looks fit to burst and investors should prepare for a correction

    60% confidence

  • Only 10 stocks comprise two-fifths (40%) of the S&P 500's total index power, reflecting extreme concentration

    60% confidence

  • Firms that have yet to produce earnings are overvalued relative to their stock price

    60% confidence

  • More than 330 S&P 500 components are currently trading 20-40% below their previous highs

    60% confidence

  • The current market exhibits 'speculative' and 'exponential price action'

    60% confidence

  • The bull & bear indicator is at an extreme high level

    60% confidence

  • Investors should lean into bonds as a defensive strategy to mitigate damage from a potential equity market correction

    60% confidence

  • Only 21 stocks led the S&P 500 to its recent record closing high, mirroring the 20 stocks that drove the index at the dot-com bubble's peak in 2000

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,564 source documents archived
Query this data → isubstrate.com